Europska Unija - slovenski - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - odpoved srca - angiotensin ii antagonisti, druge kombinacije, agente, ki delujejo na renin-angiotensin sistem - paediatric heart failureentresto is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction. adult heart failureentresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.

Europska Unija - slovenski - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propandiol monohidrat - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - zdravila, ki se uporabljajo pri diabetesu - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. poleg drugimi zdravili za zdravljenje diabetesa tipa 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 in 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Europska Unija - slovenski - EMA (European Medicines Agency)

novartis europharm limited - sacubitril, valsartan - odpoved srca - sredstva, ki delujejo na sistem renin-angiotenzin - paediatric heart failureneparvis is indicated in children and adolescents aged one year or older for treatment of symptomatic chronic heart failure with left ventricular systolic dysfunction (see section 5. adult heart failureneparvis is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction (see section 5.

Europska Unija - slovenski - EMA (European Medicines Agency)

astrazeneca ab - metformin hidroklorid, dapagliflozin propanediol monohidrat - diabetes mellitus, tip 2 - drugs used in diabetes, combinations of oral blood glucose lowering drugs - xigduo je navedeno pri odraslih za zdravljenje diabetesa tipa 2 bolezni, kot dodatek k prehrani in izvajanje:• pri bolnikih, premalo nadzorovana na njihovo maksimalno dopustne odmerek metforminom sam • v kombinaciji z drugimi zdravili za zdravljenje sladkorne bolezni pri bolnikih zadostno nadzorovana z metforminom in teh zdravil• pri bolnikih, ki se že zdravijo z kombinacijo dapagliflozin in metforminom kot ločene tablete. za študijski rezultati glede kombinacija terapij, vplivi na glycaemic nadzor in srčno-žilne dogodke, in populacije, ki je študiral glej poglavji 4. 4, 4. 5 in 5.

Europska Unija - slovenski - EMA (European Medicines Agency)

gen.orph - miglustat - gaucher bolezen - drugi zdravljene bolezni prebavil in presnove izdelki, - miglustat gen. zdravilo orph je indicirano za oralno zdravljenje odraslih bolnikov z blago do zmerno gaucherjevo boleznijo tipa 1. miglustat gen. orph se lahko uporablja le pri zdravljenju bolnikov, za katere encim nadomestno zdravljenje, je neustrezna. miglustat gen. orph je primerna za zdravljenje progresivne nevrološke manifestacije pri odraslih bolnikih in pediatričnih bolnikih z niemann-pick tip c bolezen.

Europska Unija - slovenski - EMA (European Medicines Agency)

dipharma arzneimittel gmbh - miglustat - gaucher bolezen - drugi proizvodi prebavnega trakta in metabolizma - miglustat dipharma je označen za oralno zdravljenje odraslih bolnikov z blago do zmerno tipa 1 gaucher bolezni. miglustat dipharma se lahko uporablja le pri zdravljenju bolnikov, za katere encim nadomestno zdravljenje, je neustrezna. miglustat dipharma je primerna za zdravljenje progresivne nevrološke manifestacije pri odraslih bolnikih in pediatričnih bolnikih z niemann-pick tip c bolezen.

Europska Unija - slovenski - EMA (European Medicines Agency)

astrazeneca ab - metformin hidroklorid, saxagliptin, dapagliflozin - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - qtrilmet je navedeno pri odraslih, starih 18 let in več, z vrsto 2 sladkorna bolezen:za izboljšanje glycaemic nadzora, ko je z metforminom ali brez sulfonil sečnine (su) in bodisi saxagliptin ali dapagliflozin ne zagotavlja primerne glycaemic nadzor. ko se že zdravijo z metforminom in saxagliptin in dapagliflozin.

Europska Unija - slovenski - EMA (European Medicines Agency)

heron therapeutics, b.v. - bupivacaine, meloxicam - bolečina, postoperativna - anestetiki - zynrelef is indicated for treatment of somatic postoperative pain from small- to medium-sized surgical wounds in adults (see section 5.

Europska Unija - slovenski - EMA (European Medicines Agency)

sanofi b.v. - olipudase alfa - acid sphingomyelinase deficiency (asmd) type a/b or type b - drugi zdravljene bolezni prebavil in presnove izdelki, - xenpozyme is indicated as an enzyme replacement therapy for the treatment of non-central nervous system (cns) manifestations of acid sphingomyelinase deficiency (asmd) in paediatric and adult patients with type a/b or type b.

Europska Unija - slovenski - EMA (European Medicines Agency)

otsuka pharmaceutical netherlands b.v. - voclosporin - lupus nephritis - imunosupresivi - lupkynis is indicated in combination with mycophenolate mofetil for the treatment of adult patients with active class iii, iv or v (including mixed class iii/v and iv/v) lupus nephritis (ln).